Late cardiovascular toxicity following chemotherapy for germ cell tumors

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 4, 2012, Pages 537-544

  Feldman, Darren R ^a   Schaffer, Wendy L ^a   Steingart, Richard M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; C REACTIVE PROTEIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TESTOSTERONE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

ARTERIAL WALL THICKNESS; BODY MASS; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CARDIOTOXICITY; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GERM CELL TUMOR; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHESIS; MICROALBUMINURIA; MULTIPLE CYCLE TREATMENT; OBESITY; ORCHIECTOMY; RAYNAUD PHENOMENON; REVIEW; TESTIS NONSEMINOMA CANCER; TESTOSTERONE BLOOD LEVEL; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; VASOMOTOR REFLEX;

EID: 84860720401     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0051     Document Type: Review

References (43)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Horner MJ, Ries LA, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975-2006/. Accessed February 6, 2012.
3. Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 1981;41:3275-3280. (Pubitemid 11063588)
4. Feldman DR, Bosl GJ, Sheinfeld J, et al. Medical treatment of advanced testicular cancer. JAMA 2008;299:672-684. (Pubitemid 351252727)
5. Efstathiou E, Logothetis CJ. Review of late complications of treatment and late relapse in testicular cancer. J Natl Compr Canc Netw 2006;4:1059-1070. (Pubitemid 44845493)
6. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977;87:293-298. (Pubitemid 8177356)
7. Edwards GS, Lane M, Smith FE. Long-term treatment with cis-dichlorodiammineplatinum(II)-vinblastine-bleomycin: possible association with severe coronary artery disease. Cancer Treat Rep 1979;63:551-552. (Pubitemid 9217571)
8. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-1732. (Pubitemid 30220551)
9. Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-1523. (Pubitemid 46594104)
10. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467-475. (Pubitemid 46630466)
11. van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25:4370-4378. (Pubitemid 350013842)
12. Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010;28:4649-4657.
13. Pliarchopoulou K, Pectasides D. Late complications of chemotherapy in testicular cancer. Cancer Treat Rev 2010;36:262-267.
14. Vogelzang NJ, Bosl GJ, Johnson K, et al. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981;95:288-292. (Pubitemid 11052696)
15. Glendenning JL, Barbachano Y, Norman AR, et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010;116:2322-2331.
16. Brydoy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009;101:1682-1695.
17. Bokemeyer C, Berger CC, Kuczyk MA, et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923-2932. (Pubitemid 26371450)
18. Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002;13:229-236. (Pubitemid 34704974)
19. Bissett D, Kunkeler L, Zwanenburg L, et al. Long-term sequelae of treatment for testicular germ cell tumours. Br J Cancer 1990;62:655-659. (Pubitemid 20340585)
20. Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004;40:701-706. (Pubitemid 38326620)
21. Hansen SW, Olsen N. Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold. J Clin Oncol 1989;7:940-942. (Pubitemid 19172469)
22. Heier MS, Nilsen T, Graver V, et al. Raynaud's phenomenon after combination chemotherapy of testicular cancer, measured by laser Doppler flowmetry. A pilot study. Br J Cancer 1991;63:550-552.
23. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997;15:1837-1843. (Pubitemid 27209512)
24. Dirix LY, Libura M, Libura J, et al. In vitro toxicity studies with mitomycins and bleomycin on endothelial cells. Anticancer Drugs 1997;8:859-868. (Pubitemid 27487800)
25. Shi Y, Inoue S, Shinozaki R, et al. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res 1998;89:757-767. (Pubitemid 28401162)
26. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-426. (Pubitemid 32681484)
27. Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005;23:9130-9137.
28. Vaughn DJ, Palmer SC, Carver JR, et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008;112:1949-1953. (Pubitemid 351574070)
29. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22. (Pubitemid 29024679)
30. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002;110:835-842.
31. Davis CA, Nick HS, Agarwal A. Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 2001;12:2683-2690. (Pubitemid 33115415)
32. Togna GI, Togna AR, Franconi M, et al. Cisplatin triggers platelet activation. Thromb Res 2000;99:503-509.
33. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 1979;90:929-931. (Pubitemid 9244593)
34. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980;208:198-200. (Pubitemid 10072143)
35. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985;56:2765-2770. (Pubitemid 16216283)
36. Haugnes HS, Aass N, Fossa SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007;18:241-248. (Pubitemid 46323088)
37. Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23:3718-3725.
38. Sagstuen H, Aass N, Fossa SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005;23:4980-4990. (Pubitemid 46224004)
39. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716. (Pubitemid 35403784)
40. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
41. Traish AM, Guay A, Feeley R, et al. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009;30:10-22.
42. Vaughn DJ, Gignac GA, Meadows AT. Long-term medical care of testicular cancer survivors. Ann Intern Med 2002;136:463-470. (Pubitemid 34233177)
43. Hentrich M, Fegg MJ, Meiler S, et al. Smoking cessation in long-term survivors of germ cell tumour. J Cancer Res Clin Oncol 2006;132:557-560. (Pubitemid 44078524)